Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study

Sekaggya-Wiltshire, Christine, Castelnuovo, Barbara, Von Braun, Amrei, Musaazi, Joseph, Muller, Daniel, Buzibye, Allan, Gutteck, Ursula, Henning, Lars, Ledergerber, Bruno, Corti, Natascia, Lamorde, Mohammed, Fehr, Jan, and Kambugu, Andrew (2017) Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study. BMJ Open, 7 (9). e014679.

PDF (Published Version) - Published Version
Available under License Creative Commons Attribution Non-commercial.

Download (621kB) | Preview
View at Publisher Website:


© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. Purpose Tuberculosis (TB) is a leading cause of death among people living with HIV in sub-Saharan Africa. Several factors influence the efficacy of TB treatment by leading to suboptimal drug concentrations and subsequently affecting treatment outcome. The aim of this cohort is to determine the association between anti-TB drug concentrations and TB treatment outcomes. Participants Patients diagnosed with new pulmonary TB at the integrated TB-HIV outpatient clinic in Kampala, Uganda, were enrolled into the study and started on first-line anti-TB treatment. Findings to date Between April 2013 and April 2015, the cohort enrolled 268 patients coinfected with TB/HIV; 57.8% are male with a median age of 34 years (IQR 29-40). The median time between the diagnosis of HIV and the diagnosis of TB is 2 months (IQR 0-22.5). The majority of the patients are antiretroviral therapy naive (75.4%). Our population is severely immunosuppressed with a median CD4 cell count at enrolment of 163 cells/μL (IQR 46-298). Ninety-nine per cent of the patients had a diagnosis of pulmonary TB confirmed by sputum microscopy, Xpert/RIF or culture and 203 (75.7%) have completed TB treatment with 5099 aliquots of blood collected for pharmacokinetic analysis. Future plans This cohort provides a large database of well-characterised patients coinfected with TB/HIV which will facilitate the description of the association between serum drug concentrations and TB treatment outcomes as well as provide a research platform for future substudies including evaluation of virological outcomes. Trial registration number NCT01782950; Pre-results.

Item ID: 65372
Item Type: Article (Research - C1)
ISSN: 2044-6055
Keywords: anti-tuberculosis drugs, cohort, pharmacokinetics, set-up, therapeutics, tuberculosis
Copyright Information: This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Funders: Makerere University, University of Zurich
Date Deposited: 25 Feb 2021 02:29
FoR Codes: 32 BIOMEDICAL AND CLINICAL SCIENCES > 3207 Medical microbiology > 320701 Medical bacteriology @ 100%
SEO Codes: 92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920109 Infectious Diseases @ 100%
Downloads: Total: 812
Last 12 Months: 14
More Statistics

Actions (Repository Staff Only)

Item Control Page Item Control Page